Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 4Gastrointestinal 3Gynecologic 2Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Mesothelioma 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × amatuximab × Gynecologic × Clear all
NCT01521325 2016-09-30

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Morphotek

Phase 1 Completed
6 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00325494 2014-07-17

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Morphotek

Phase 1 Completed
24 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡